Primary Immunodeficiency Disorders: CVID, Selective IgA Deficiency, and Clinical Workup

Primary immunodeficiency disorders (PIDs) are inherited defects in immune system development or function that predispose patients to recurrent infections, autoimmunity, malignancy, and allergic diseases. Among the most clinically relevant PIDs are Common Variable Immunodeficiency (CVID) and Selective IgA Deficiency.

[KEY_CONCEPT] Common Variable Immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults, characterized by hypogammaglobulinemia with impaired antibody responses and recurrent bacterial infections. The prevalence ranges from 1:25,000 to 1:50,000 in the general population.

Selective IgA Deficiency is defined as serum IgA levels <7 mg/dL (0.07 g/L) with normal IgG and IgM levels. It represents the most common primary immunodeficiency overall, affecting approximately 1:300 to 1:700 individuals of European descent.

[HIGH_YIELD] The clinical spectrum of these disorders varies dramatically:

[CLINICAL_PEARL] Most patients with selective IgA deficiency are asymptomatic, but those who develop symptoms typically present with recurrent sinopulmonary infections, gastrointestinal disorders, and increased autoimmune disease risk.

The pathophysiology involves defective B-cell maturation and antibody production. In CVID, the underlying genetic defects affect various aspects of B-cell development, T-cell help, or antibody class switching. Multiple genetic variants have been identified, including mutations in TACI, BAFF-R, and PIK3CD genes.

The clinical presentation of primary immunodeficiency varies significantly between CVID and selective IgA deficiency, though both share common features of increased infection susceptibility.

CVID Clinical Features

[HIGH_YIELD] Classic CVID presentation includes:

• Recurrent sinopulmonary infections (>90% of patients)
• Bronchiectasis (develops in 60-70% if untreated)
• Gastrointestinal manifestations (40-60%)
• Autoimmune complications (25-30%)
• Malignancy risk (lymphoma, gastric cancer)

Infection Pattern in CVID:

• Bacterial infections: Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus
• Atypical organisms: Mycoplasma, Ureaplasma
• Opportunistic infections: Pneumocystis jirovecii, Cryptosporidium

[CLINICAL_PEARL] CVID patients may develop granulomatous disease (10-15%), presenting as pulmonary nodules, lymphadenopathy, or hepatosplenomegaly, which can mimic sarcoidosis.

Selective IgA Deficiency Clinical Features

Most patients (85-90%) are asymptomatic, but symptomatic patients may present with:

• Recurrent upper respiratory tract infections
• Sinusitis and otitis media
• Gastrointestinal disorders (celiac disease, IBD)
• Allergic diseases (asthma, atopic dermatitis)
• Autoimmune conditions (SLE, rheumatoid arthritis)

[KEY_CONCEPT] Warning signs suggesting progression from IgA deficiency to CVID:

• Development of IgG subclass deficiencies
• Onset of lower respiratory tract infections
• Poor vaccine responses
• New autoimmune manifestations

Age-Related Presentation Patterns:

Pediatric Presentation: ├── Recurrent otitis media/sinusitis ├── Failure to thrive ├── Chronic diarrhea └── Delayed diagnosis common

Adult Presentation: ├── Chronic sinusitis ├── Bronchiectasis ├── Autoimmune complications └── Malignancy (late manifestation)

[HIGH_YIELD] Red flags for underlying immunodeficiency:

• >8 otitis media episodes/year in children
• >2 pneumonias/year
• Failure to thrive despite treatment
• Family history of immunodeficiency
• Recurrent severe infections with encapsulated bacteria

The diagnostic approach to primary immunodeficiency requires a systematic evaluation combining clinical history, laboratory testing, and functional immune assessments.

CVID Diagnostic Criteria (ESID/PAGID)

[KEY_CONCEPT] Essential Criteria (ALL must be present):

□ Age >4 years at symptom onset □ Serum IgG >2 SD below age-adjusted normal □ Serum IgA and/or IgM >2 SD below age-adjusted normal □ Poor antibody responses to vaccines □ Exclusion of secondary causes of hypogammaglobulinemia

Laboratory Thresholds:

[CLINICAL_PEARL] Vaccine response testing is crucial - poor responses to both protein (tetanus, diphtheria) and polysaccharide (pneumococcal) vaccines help differentiate CVID from other causes of hypogammaglobulinemia.

Selective IgA Deficiency Diagnostic Criteria

□ Serum IgA <7 mg/dL (0.07 g/L) □ Normal serum IgG and IgM levels □ Age >4 years (allows time for IgA maturation) □ Exclusion of secondary causes

Comprehensive Immunological Workup

Initial Screening Tests:

First-Line Laboratory Studies: ├── Complete blood count with differential ├── Quantitative immunoglobulins (IgG, IgA, IgM, IgE) ├── IgG subclasses (if IgG low-normal) ├── Vaccine titers (if age-appropriate vaccination history) └── Complement levels (C3, C4, CH50)

Advanced Functional Testing:

• Vaccine challenge studies (pneumococcal, tetanus/diphtheria)
• Lymphocyte phenotyping (CD3, CD4, CD8, CD19, CD56)
• Lymphocyte proliferation studies (mitogen and antigen responses)
• Specific antibody responses (isohemagglutinins, specific pathogen titers)

[HIGH_YIELD] Differential Diagnosis Considerations:

Secondary Causes to Exclude:

• Medications: Immunosuppressants, anticonvulsants, sulfasalazine
• Malignancy: Hematologic malignancies, solid tumors
• Protein loss: Nephrotic syndrome, protein-losing enteropathy
• Infections: HIV, EBV, CMV

[CLINICAL_PEARL] Transient hypogammaglobulinemia of infancy must be distinguished from primary immunodeficiency - immunoglobulin levels typically normalize by age 2-4 years.

Management of primary immunodeficiency requires a multifaceted approach combining infection prevention, immunoglobulin replacement, and treatment of complications.

CVID Management Algorithm

CVID Diagnosis Confirmed ↓ Assess Disease Severity ├── Mild (occasional infections) │ ├── Prophylactic antibiotics │ ├── Aggressive infection treatment │ └── Regular monitoring └── Moderate-Severe (recurrent infections/complications) ├── Immunoglobulin replacement therapy (IgRT) ├── Prophylactic antibiotics if needed └── Complication management

Ongoing Monitoring: ├── Pulmonary function tests (annual) ├── High-resolution chest CT (every 2-3 years) ├── Liver function monitoring └── Cancer surveillance

[HIGH_YIELD] Immunoglobulin Replacement Therapy (IgRT):

IVIG (Intravenous) Dosing:

• Standard dose: 400-600 mg/kg every 3-4 weeks
• Target trough IgG: >500-800 mg/dL
• Higher doses (600-800 mg/kg) for severe disease or complications

SCIG (Subcutaneous) Dosing:

• Weekly administration: 100-200 mg/kg/week
• Facilitates self-administration
• Fewer systemic side effects
• More stable IgG levels

[CLINICAL_PEARL] IgRT indications in CVID:

• Recurrent bacterial infections
• Bronchiectasis or chronic lung disease
• Failure to respond to appropriate antibiotic therapy
• Poor quality of life due to infections

Selective IgA Deficiency Management

Asymptomatic Patients:

• No specific treatment required
• Annual monitoring for symptom development
• Avoid anti-IgA containing blood products (anaphylaxis risk)
• Genetic counseling if family planning

Symptomatic Patients:

Symptomatic IgA Deficiency Management: ├── Aggressive infection treatment │ ├── Appropriate antibiotic therapy │ ├── Consider prophylaxis if severe/recurrent │ └── Vaccination optimization ├── Comorbidity management │ ├── Autoimmune disease treatment │ ├── Allergy management │ └── GI disorder treatment └── Monitoring for progression to CVID

[KEY_CONCEPT] Special Considerations for IgA Deficiency:

• Blood product precautions: Use washed red blood cells or IgA-deficient blood products
• Anti-IgA antibody screening before any blood transfusion
• IgRT is contraindicated (risk of anaphylaxis)

Infection Management Strategies

Antibiotic Prophylaxis Indications:

• Recurrent sinopulmonary infections (>4-6 episodes/year)
• Bronchiectasis with frequent exacerbations
• Post-infectious complications

Prophylaxis Regimens:

[HIGH_YIELD] Vaccination Guidelines:

• Live vaccines contraindicated in CVID patients on IgRT
• Inactivated vaccines recommended (influenza, pneumococcal, Tdap)
• Response monitoring essential to guide therapy adjustments
• Household contacts should receive live virus vaccines as appropriate

Complication Management:

• Autoimmune diseases: Standard immunosuppressive therapy with infectious disease monitoring
• Granulomatous disease: Corticosteroids, methotrexate, or anti-TNF agents
• Malignancy surveillance: Regular screening, especially for lymphoma and gastric cancer

[CLINICAL_PEARL] Quality of life considerations: Patients on chronic IgRT often experience significant improvement in energy levels, reduced infection frequency, and enhanced overall well-being within 6-12 months of therapy initiation.

Primary immunodeficiency disorders carry significant long-term morbidity if not properly managed, with complications affecting multiple organ systems.

CVID Complications

[HIGH_YIELD] Pulmonary Complications (Most Common):

• Bronchiectasis (60-70% of patients)
• Chronic obstructive pulmonary disease
• Pulmonary fibrosis
• Granulomatous lung disease
• Increased risk of lung cancer

Bronchiectasis Development Timeline:

Bronchiectasis Progression in CVID: Diagnosis → 5 years: 30-40% develop bronchiectasis 5-10 years: 50-60% have bronchiectasis

10 years: 60-70% affected

Risk Factors: ├── Delayed diagnosis (>5 years) ├── Poor IgRT compliance ├── Inadequate infection treatment └── Concomitant asthma/allergies

[CLINICAL_PEARL] Early IgRT initiation (within 4-7 years of symptom onset) significantly reduces bronchiectasis development from 77% to 31%.

Autoimmune & Inflammatory Complications

CVID-Associated Autoimmunity (25-30%):

[KEY_CONCEPT] Granulomatous disease in CVID can mimic sarcoidosis but typically has a more aggressive course and may predict increased autoimmune complications.

Malignancy Risk

CVID patients have 10-20x increased cancer risk:

• Non-Hodgkin lymphoma (most common, 5-10% lifetime risk)
• Gastric adenocarcinoma (46x increased risk)
• Thymoma (rare but important association)

Cancer Surveillance Protocol:

CVID Cancer Screening: ├── Annual CBC with differential ├── LDH, β2-microglobulin monitoring ├── CT chest/abdomen/pelvis every 2-3 years ├── Upper endoscopy every 3-5 years (after age 40) └── Age-appropriate general cancer screening

Selective IgA Deficiency Complications

[HIGH_YIELD] Risk of Progression to CVID:

• 2-3% of IgA-deficient patients eventually develop CVID
• Monitoring indicators: Development of IgG deficiency, recurrent lower respiratory infections

Associated Conditions:

• Celiac disease (10-15x increased prevalence)
• Inflammatory bowel disease (2-3x increased risk)
• Autoimmune disorders (SLE, RA, type 1 diabetes)
• Allergic diseases (asthma, atopic dermatitis)

Prognosis & Quality of Life

CVID Prognosis Factors:

Favorable Prognosis:

• Early diagnosis and treatment
• Good adherence to IgRT
• Absence of autoimmune complications
• No bronchiectasis at diagnosis

Poor Prognosis Indicators:

• Granulomatous disease
• Autoimmune cytopenias
• Advanced bronchiectasis
• Malignancy development

[CLINICAL_PEARL] Life expectancy in CVID approaches normal with appropriate treatment, but quality of life may be impacted by chronic complications and treatment burden.

Long-term Monitoring Strategy:

Patient Education Priorities:

• Recognition of infection symptoms requiring urgent care
• Importance of IgRT compliance
• Avoidance of live vaccines
• Blood transfusion precautions (especially IgA deficiency)
• Family screening recommendations